Preclinical evaluation of DO3P-AME-DO3P: A polyazamacrocyclic methylene phosphonate for diagnosis and therapy of skeletal metastases

Bioconjugate Chemistry

Volumn 22, Issue 2, 2011, Pages 244-255

  Tanwar, Jyoti ^a,b   Datta, Anupama ^a   Tiwari, Anjani Kumar ^a   Thirumal, Meganathan ^b   Chuttani, Krishna ^a   Mishra, Anil Kumar ^a  

^a INSTITUTE OF NUCLEAR MEDICINE AND ALLIED SCIENCES   (India)

^b UNIVERSITY OF DELHI   (India)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING ENERGY; BLOOD; CELL CULTURE; CELL PROLIFERATION; LYMPHOCYTES; PATHOLOGY; PHOSPHATE MINERALS; SAMARIUM COMPOUNDS; URANIUM COMPOUNDS;

ACETAMIDO; BINDING AFFINITIES; BONE MINERALS; HIGH PURITY; IN-VITRO; PHOSPHONATES; PHOSPHONIC ACIDS; SPECIFIC ACTIVITY; STABILITY CONSTANTS; SYNTHESISED;

BONE;

10' BIS(ACETAMIDO) ETHANE BIS[1,4,7 TRI(METHYLENE PHOSPHONIC ACID) 1,4,7,10 TETRAAZACYCLODODECANE] TC 99M; HYDROXYAPATITE; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; BONE METASTASIS; BONE MINERAL; CLINICAL EVALUATION; DIAGNOSTIC VALUE; DRUG BINDING; DRUG BLOOD LEVEL; DRUG BONE LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG MUSCLE LEVEL; DRUG STABILITY; DRUG SYNTHESIS; DRUG UPTAKE; HUMAN; HUMAN CELL; ISOTOPE LABELING; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOCLAST; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

MUS; ORYCTOLAGUS CUNICULUS;

EID: 79951696923     PISSN: 10431802     EISSN: 15204812     Source Type: Journal    
DOI: 10.1021/bc100382c     Document Type: Article

References (50)

1. Bagi, C. M. (2005) Targeting of therapeutic agents to bone to treat metastatic cancer Adv. Drug Delivery Rev. 57, 995-1010 (Pubitemid 40692289)
2. Wang, D., Miller, S., Sima, M., Kopeckova, P., and Kopecek, J. (2003) Synthesis and evaluation of water-soluble polymeric bone-targeted drug delivery systems Bioconjugate Chem. 14, 853-859
3. 188Re-HEDP combined with capecitabine in hormone- refractory prostate cancer patients with bone metastases: A phase I safety and toxicity study Eur. J. Nucl. Med. Mol. Imaging 36, 1425-1433
4. 99mTc-DOTMP and its preclinical evaluation as a multidentate imaging agent for skeletal metastases Cancer Biother. Radiopharm. 24 (1) 123-128
5. 99mTc chelate-conjugated alendronate for development of specific radiopharmaceuticals Cancer Biother. Radiopharm. 24, 209-214
6. Neale, J. R., Richter, N. B., Merten, K. E., Taylor, K. G., Singh, S., Waite, L. C., Emery, N. K., Smith, N. B., Cai, J., and Pierce, W. M., Jr. (2009) Bone selective effect of an estradiol conjugate with a novel tetracycline-derived bone-targeting agent Bioorg. Med. Chem. Lett. 19, 680-683
7. Wang, D., Miller, S. C., Kopeckova, P., and Kopecek, P. (2005) Bone- targeting macromolecular therapeutics Adv. Drug Delivery Rev. 57, 1049-1076
8. Mitterhauser, M. and Toegel, S. (2008) What to consider in the development of new bone seekers: mechanistic and tracer- related aspects Nucl. Med. Biol. 35, 817-824
9. Houghton, T. J., Tanaka, K. S. E., Kang, T., Dietrich, E., Lafontaine, Y., Delorme, D., Ferreira, S. S., Viens, F., Arhin, F. F., Sarmiento, I., Lehoux, D., Fadhil, I., Laquerre, K., Liu, J., Ostiguy, V., Poirier, H., Moeck, G., Parr, T. R., and Far, A. R., Jr. (2008) Linking Bisphosphonates to the free amino groups in fluoroquinolones: Preparation of osteoblastic prodrugs for the prevention of osteomyelitis J. Med. Chem. 51, 6955-6969
10. Merrick, M. V. (1975) Review article-bone scanning Br. J. Radiol. 48, 327-351
11. Lin, J. H. (1996) Bisphosphonate: A review of their pharmacokinetics properties Bone 18 (2) 75-85 (Pubitemid 26092586)
12. Francis, M. D. and Valent, D. J. (2007) Historical perspective on the clinical development of bisphosphonates in the treatment of bone diseases J. Musculoskelet. Neuronal Interact. 7 (1) 2-8
13. 99mTc-EC with aminomethylenediphosphonate in the search for a bone tracer with fast clearance from soft tissue Bioconjugate Chem. 13, 16-22
14. 18F-fluoride PET/CT J. Nucl. Med. 49, 414-421
15. Peterson, J. J., Kransdorf, M. J., and O'Connor, M. I. (2003) Diagnosis of occult bone metastases: positron emission tomography Clin. Orthop. Relat. Res. 415 (suppl) S120-S128
16. Bombardieri, E. and Crippa, F. (2001) PET imaging in breast cancer J. Nucl. Med. 45, 245-256
17. Hamaoka, T., Madewell, J. E., Podoloff, D. A., Hortobagyi, G. N., and Ueno, N. T. (2004) Bone imaging in metastatic breast cancer J. Clin. Oncol. 22, 2942-2953
18. Liu, S. and Edwards, D. S. (2001) Bifunctional chelators for therapeutic lanthanide radiopharmaceuticals Bioconjugate Chem. 12, 7-34
19. Thom, V. J., Fox, C. C., Boeyens, J. C. A., and Hancock, R. D. (1984) Molecular mechanics and crystallographic study of hole sizes in nitrogen-donor tetraazamacrocycles J. Am. Chem. Soc. 106, 5947-5955
20. Chang, C. A., Liu, Y. L., Chen, C. Y., and Chou, X. M. (2001) Ligand preorganization in metal ion complexation: Molecular mechanics/dynamics, kinetics and laser excited luminiscencs studies of trivalent lanthanide complex formation with macrocyclic ligands TETA and DOTA Inorg. Chem. 40, 3448-3455
21. Izatt, R. M., Pawlak, K., Bradshaw, J. S., and Bruening, R. L. (1995) Thermodynamic and kinetic data for macrocycle interaction with cations, anions and neutral molecules Chem. Rev. 95, 2529-2586
22. 186Re chelate-conjugated bisphosphonate for the development of new radiopharmaceuticals for bones Nucl. Med. Biol. 34, 79-87
23. 153Sm- EDTMP for bone pain palliation in skeletal metastases Eur. J. Nucl. Med. Mol. Imaging 31 (1) s171-s178
24. 177Lu-EDTMP, a potential bone pain palliation agent Nucl. Med. Biol. 37, 215-226
25. 90Y]DOTA-conjugated bisphosphonate for treatment of painful bone metastases Nucl. Med. Biol. 36, 129-135
26. 205Bi-DOTMP, visualizing bone deposition patterns with autoradiography Nucl. Med. Biol. 28, 425-433
27. OEt) J. Inorg. Biochem. 102, 1531-1540
28. 188Re-labeled gemcitabine/bisphosphonate (Gem-BP): a multifunctional bone specific agent as a potential treatment for bone metestases Eur. J. Nucl. Med. Mol. Imaging 35, 1240-1248
29. 4dota and comparative kinetic study of yttrium(III) complexes Dalton Trans. 535-549
30. Volkert, W. A. and Hoffman, T. J. (1999) Therapeutic radiopharmaceuticals Chem. Rev. 99, 2269-2292
31. Geraldes, C. F. G. C., Sherry, A. D., and Cacheris, W. P. (1989) Synthesis, protonation sequence, and NMR studies of polyazamacrocyclic methylenephosphonates Inorg. Chem. 28, 3336-3341
32. 8DOTP) Inorg. Chem. 31, 4422-4424
33. Delgado, R., Siegfried, L. C., and Kaden, T. A. (1990) Protonation studies and complexation properties of tetraazamacrocyclic methylenephosphonates with earth-alkali metals Helv. Chim. Acta 73, 140-148
34. 5- outer sphere relaxation enhancement promoted by nitrogen bases Magn. Reson. Med. 30, 583-591
35. Sherry, A. D., Ren, J., Huskens, J., Brucher, E., Toth, E., Geraldes, C. F. C. G., Castro, M. M. C. A., and Cacheris, W. P. (1996) Characterization of lanthanide(III) DOTP complexes: Thermodynamics, protonation and coordination to alkali metal ions Inorg. Chem. 35, 4604-4612
36. - Eur. J. Inorg. Chem. 813-820
37. 3+ ions as MRI contrast agents Magn. Reson. Med. 9, 94-104
38. 166Ho J. Magn. Reson. 97, 290-304
39. 5- Eur. J. Inorg. Chem. 4179-4186
40. 3+ complexes: An attempt towards calcium-sensitive MRI contrast agents Inorg. Chem. 47 (4) 1370-1381
41. a values of the ionizable groups in ligands within a given pH range.
42. Krakowiak, K. E. and Bradshaw, J. S. (2000) Synthesis of azacrown macrocycles and related compounds by a crablike cyclization method: A short review Ind. Eng. Chem. Res. 39, 3499-3507
43. Duarte, L. F., Teixeira, F. C., and Fausto, R. (2010) Molecular modelling of the interaction of novel hydroxy- and aminobisphosphonates with hydroxyapatite Arkivoc (V) 117-127
44. Takahashi, N., Udagawa, N., and Suda, T. (1999) A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/RANKL, regulates osteoclast differentiation and function Biochem. Biophy. Res. Commun. 256, 449-455
45. Yasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Goto, M., Mochizuki, S. H., Tsuda, E., Morinaga, T., Udagawa, N., Takahashi, N., Suda, T., and Higashio, K. (1999) A novel molecular mechanism modulating osteoclast differentiation and function Bone 25, 109-113
46. 99mTc-based multidentate phosphonate chelate: 5-amino-1,3- bis(ethylamine-(N, N-dimethyl diphosphonic acid) acetamido) benzene Biol. Med. Chem. 15, 1138-1145
47. 99mTc for the detection of skeletal metastases Nucl. Med. Commun. 27, 619-626
48. 99mTc-diphosphonate uptake mechanism on bone Bone scanning in clinical practice 7-17
49. Kalman, F. K., Baranyai, Z., Toth, I., Banyai, I., Kiraly, R., Brucher, E., Aime, S., Sun, X., Sherry, A. D., and Kovacs, Z. (2008) synthesis, protonation, kinetic, and NMR studies of 1,4,7,10-tetraazacyclododecane-1,7- bis(acetic acid)-4,10-bis(methylenephosphonic acid) (DO2A2P) and its complexes with Ca(II), Cu(II), Zn(II) and lanthanide(III) ions Inorg. Chem. 47, 3851-3862
50. Anderegg, G., Arnaud-Neu, F., Delgado, R., Felcman, J., and Popov, J. K. (2005) Critical evaluation of stability constants of metal complexes of complexones for biomedical and environmental applications (IUPAC technical report) Pure Appl. Chem. 77, 1445-1495